Apellis Pharmaceuticals, Inc.
APLS
Pozycja w akcjach
#3327
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Cena akcji
$41.03
Ostatnia synchronizacja: 2026-05-15
Kapitalizacja rynkowa
$5.25B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
67.33%
Kraj
US
Handel Apellis Pharmaceuticals, Inc. (APLS)
Kategoria
Healthcare
Marża operacyjna dla Apellis Pharmaceuticals, Inc. (APLS)
Marża operacyjna na dzień October 2026 TTM: 14.95%
Według najnowszych raportów finansowych i ceny akcji Apellis Pharmaceuticals, Inc., bieżąca marża operacyjna (TTM) wynosi 14.95%. Na koniec 2023 wynosiła -130.39%.
Historia marży operacyjnej dla Apellis Pharmaceuticals, Inc. od 2013 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 14.95% | -170.82% |
| 2024 | -21.11% | -83.81% |
| 2023 | -130.39% | -83.46% |
| 2022 | -788.38% | -2.15% |
| 2021 | -805.67% | 844.85% |
| 2020 | -85.27% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -97.42% |
US
|
|
| -149.01% | -109.97% |
US
|
|
| 25.57% | -98.29% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.07% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.